Kim R. Tsuchimoto - 01 Jan 2022 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Financial Officer
Signature
/s/ Kim R. Tsuchimoto
Issuer symbol
MNPR
Transactions as of
01 Jan 2022
Net transactions value
-$1,621
Form type
4
Filing time
04 Jan 2022, 13:31:21 UTC
Previous filing
04 Jan 2022
Next filing
04 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +1,231 +29% 5,420 01 Jan 2022 Direct F1
transaction MNPR Common Stock Tax liability $1,621 -505 -9.3% $3.21 4,915 01 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -1,231 -33% $0.000000 2,461 01 Jan 2022 Common Stock 1,231 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 On January 31, 2020 the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.